These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Site Enhances New Modality CRDMO Platform Capacity for Customers
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The first of four planned modules at the new plant is expected to come online by summer 2026
Expanding US operations to address the increased demand for API development and manufacturing
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Subscribe To Our Newsletter & Stay Updated
